ARVN · CIK 0001655759
ARVINAS, INC.
What ARVINAS, INC. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
ARVINAS, INC. - Profile
- Industry
- Pharmaceutical PreparationsSIC 2834
- Listed on
- Nasdaq
- Employees
- 246stated 2025
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from ARVINAS, INC.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The website comes from Wikidata. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from Arvinas, Inc. Form 10-K for fiscal year 2025, Arvinas, Inc. Form 10-Q for the quarter ended 30 June 2026, Arvinas, Inc. Form 8-K dated 1 May 2026 (FDA approval of VEPPANU) and Arvinas, Inc. Form 8-K dated 4 August 2026, Exhibit 99.1 (second quarter 2026 results and corporate update), not taken from any single article.
Share price
ARVN
Description
Arvinas, Inc. is a clinical-stage biotechnology company in New Haven, Connecticut built on PROTAC (PROteolysis TArgeting Chimera) targeted protein degradation. A PROTAC is a small molecule joining a ligand for an E3 ligase to a ligand for a disease-causing protein: the resulting ternary complex tags that protein with ubiquitin and the proteasome destroys it. Unlike an inhibitor, which must keep occupying a binding pocket, one degrader acts catalytically and can clear many copies of a target, including scaffolding proteins and transcription factors treated as undruggable. Vepdegestrant (ARV-471), an oral estrogen receptor degrader partnered with Pfizer since July 2021 for $650.0 million upfront and 50/50 development cost sharing, won FDA approval on 1 May 2026 as VEPPANU in ESR1-mutated ER+/HER2- advanced breast cancer, the first approval of any PROTAC. On 11 May 2026 Arvinas and Pfizer out-licensed it globally to Rigel Pharmaceuticals for $70.0 million upfront, $15.0 million on transition, up to $320.0 million of milestones and mid-teens to mid-20s royalties, all split evenly with Pfizer. Luxdegalutamide is licensed to Novartis. The remaining pipeline is Phase 1: ARV-393, ARV-102, ARV-027 and ARV-806. Net income was $111.8 million in the first half of 2026 after a net loss of $80.8 million in 2025, and cash and marketable securities were $567.9 million at 30 June 2026.
Who owns ARVINAS, INC..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 201 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
201 managers reported a position, together holding 54.1m shares, or 83.9% of the company. The 40 largest are listed. Percentages are of the 64.5m shares outstanding at 7 May 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 04335A105, held by ameriprise, bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, franklin-resources, geode, goldman-sachs, huntington-bancshares, invesco, jpmorgan, metlife, morgan-stanley, northern-trust, pfizer, pnc, prudential-financial, raymond-james, state-street, us-bancorp, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.